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Background: Patients with schizophrenia have lower longevity than the general population as a consequence of a
combination of risk factors connected to the disease, lifestyle and the use of medications, which are related to
weight gain.
Methods: A multicentric, randomized, controlled-trial was conducted to test the efficacy of a 12-week group
Lifestyle Wellness Program (LWP). The program consists of a one-hour weekly session to discuss topics like dietary
choices, lifestyle, physical activity and self-esteem with patients and their relatives. Patients were randomized into
two groups: standard care (SC) and standard care plus intervention (LWP). Primary outcome was defined as the
weight and body mass index (BMI).
Results: 160 patients participated in the study (81 in the intervention group and 79 in the SC group). On an intent
to treat analysis, after three months the patients in the intervention group presented a decrease of 0.48 kg
(CI 95% -0.65 to 1.13) while the standard care group showed an increase of 0.48 kg (CI 95% 0.13 to 0.83; p=0.055).
At six-month follow-up, there was a significant weight decrease of −1.15 kg, (CI 95% -2.11 to 0.19) in the
intervention group compared to a weight increase in the standard care group (+0.5 kg, CI 95% -0.42–1.42, p=0.017).
Conclusion: In conclusion, this was a multicentric randomized clinical trial with a lifestyle intervention for
individuals with schizophrenia, where the intervention group maintained weight and presented a tendency to
decrease weight after 6 months. It is reasonable to suppose that lifestyle interventions may be important long-term
strategies to avoid the tendency of these individuals to increase weight.
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The use of antipsychotic medications is essential for
controlling the acute psychotic episode and to prevent
relapse of schizophrenia, but they are associated with
long-term weight gain [1]. Moreover, people with schizo-
phrenia tend to practice little physical activity, are more
prone to tobacco addiction and show preference for a* Correspondence: cattux@gmail.com
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reproduction in any medium, provided the ordiet rich in calories [2,3]. Such lifestyle, together with
the side effects induced by antipsychotics, predispose
individuals with schizophrenia be overweight or obese
[1], with a higher risk for diabetes mellitus (DM) and
cardiovascular diseases (CVD) [4], leading to a signifi-
cant reduction in life expectancy [5,6]. Weight gain is
also associated with the perception of poor quality of
life, reduced general health, and low vitality [3], thus
representing an important factor for non-adherence of
medications [7]. Moreover, obese patients are more
likely to discontinue their medication [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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improve management of patients with schizophrenia is
now widely recognized [9]. For instance, Faulkner et al.
[10] conducted a review of pharmacological and non-
pharmacological strategies for reducing or preventing
weight gain in individuals with schizophrenia. They
concluded that no single pharmacological agent is con-
sistently superior in terms of weight-loss efficacy, and
that non-pharmacological interventions which include
dietary and physical activity modifications were effective
to prevent weight gain.
Several lifestyle interventions have been tested for redu-
cing the negative consequences of weight gain, and to de-
crease incidence and prevalence of DM and metabolic
syndrome (MS) [11-14]. These lifestyles strategies for
weight-gain management have been proven to be effective
in clinical trials and include regular check-ups, lifestyle
and medication counseling, medication assessments, be-
havioral control programs, and pharmacological interven-
tion [10,15]. Most interventions used pharmacological
adjuncts or cognitive behavioral interventions for reducing
weight gain in patients with schizophrenia [10] though
very few studies used lifestyle modifications for patients
with schizophrenia [16]. Thus, the main aim of the present
study was to test the efficacy of a 12-week group Lifestyle
Wellness Program (LWP), as a strategy for weight gain
management for individuals with schizophrenia.
Methods
Lifestyle Wellness Program (LWP) is a 12-week weight
management intervention developed by Eli Lilly Labora-
tories for controlling weight gain for individuals with
schizophrenia under antipsychotic use [17]. The pro-
gram consists of a one-hour weekly session to discuss
topics like dietary choices, lifestyle, physical activity and
self-esteem with patients and their relatives [18]. The
program combines behavioural techniques such as the
use of diaries and role play to dealing with stress, and
psychoeducation components including awareness of
dietary habits. The intervention is comprised by 12
sessions as follows: a) one session for the introduction of
the intervention; b) four sessions for discussing dietary
choices using the concept of the food pyramid; c) three
sessions for discussing the importance of physical activ-
ity; d) one session for self-esteem and motivation; e) one
session for management of anxiety; and f ) one session
opened to relatives, and h) the wrap up of the program
[18]. The inclusion of relatives may be a particular fea-
ture of the program for countries where most of the
patients live with their families as is the case in Brazil.
The groups are led by mental health professionals
(nurses, occupational therapists, psychologists and
dietitians), who are trained with a manual and a set of
DVDs explaining the program.A multicentric randomized clinical trial was conducted to
compare the efficacy of this Lifestyle Wellness Program
(LWP) with controls on a standard care (SC) group. Patients
on the intervention group and on standard care group had
regular visits to the psychiatrist and attended regular sessions
of other psychosocial interventions offered by the program
they were enrolled. Participants were drawn from the
following outpatient programs: a) the Schizophrenia Pro-
gram (Programa de Esquizofrenia – PROESQ, Universidade
Federal de São Paulo); b) the Schizophrenia Program of Insti-
tute of Psychiatry- PROJESQ (Universidade de São Paulo); c)
the CAISM (Centro de Atenção Integrada à Saúde Mental)
from Irmandade Santa Casa de Misericórdia de São Paulo;
and d) the Psychosocial Community Center Luiz da Rocha
Cerqueira, which is directed by the Universidade Federal de
São Paulo, all located in the city of São Paulo.
Participants using any antipsychotic in the past three
months, presenting a diagnosis on the schizophrenia
spectrum confirmed by the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID I-P) [19], aged be-
tween 18 and 65 years old, and being clinical stable, i.e.,
reaching less than 60 in the Positive and Negative Syn-
drome Scale (PANSS) scale [20] were asked to partici-
pate. They also needed to be motivated to lose weight or
have showed some concern about weight gain.
Participants were already enrolled in the outpatient units
included in the study and were referred by either the
clinician or a mental health worker of the team.
Patients were excluded if they were not clinically stable,
in the presence of DM, or had a previous history of an
eating disorder (Anorexia and Bulimia), or drug and alco-
hol abuse. Patients were not allowed to take any medica-
tion with the intention of controlling or reducing weight.
Participants who agreed to take part in the study signed
written informed consent and were randomly assigned to
the intervention group or a standard care group using a
randomization table available on the web site www.
randomization.com. The protocol was submitted and
approved by the Ethical Committee of each center.
The primary outcome was defined as weight and body
mass index (BMI) changes. BMI was calculated as weight
in kilograms divided by the square of the height in meters.
Data on social and demographic characteristics, clinical
data and physical examination (weight, height, BMI, waist
circumference and blood pressure) were routinely re-
corded. Weight was recorded every month, in the morn-
ing, on the same scale (Kratos-cas Linea model), without
shoes, with the individuals wearing light clothes. Waist
was considered at the level of the navel. Blood pressure
was measured twice, and the mean of both measures was
considered. Measures were collected by the same investi-
gator in all assessments.
Fasting plasma glucose, insulin, total cholesterol, HDL-
cholesterol, LDL- cholesterol and triglycerides levels were
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up. A surrogate of insulin resistance, the Homeostatic
Model Assessment (HOMA-IR) was calculated at base-
line, at three and six months [21].
Blind investigators applied the following instruments to
participants of the trial at baseline and three-month follow
up: the Positive and Negative Syndrome Scale (PANSS)
[20] to evaluate the severity of the disease, the Calgary
Depression Scale [22] to assess depression, Clinical Global
Impression – Severity Scale (CGI-S) [21] and Clinical
Global Impression- Improvement Scale (CGI-I) [23] to as-
sess clinical global impression. Global functioning was
evaluated by Global Assessment of Functioning (GAF)
[24], and independent living skills by Independent Living
Skills Survey- patient version (ILSS-BR/P) [25]. Patients
were asked to reply to the following self-rated scales: The
World Health Organization's WHOQOL-BREF quality of
life assessment- WHOQoL-BREF [26], Rosenberg self-
esteem scale [27], Dietary Instrument for Nutrition Educa-
tion (DINE) to classify dietary fat (satured and unsatured
fat) and fiber intakes [28], Fagerström tolerance question-
naire to evaluate tobacco dependence [29], and Inter-
national Physical Activity Questionnaire-short version
(IPAQ) [30] to evaluate physical activity. IPAQ short form
is an instrument designed primarily for population surveil-
lance of physical activity among adults. IPAQ classifies
physical activity into three categories: walking, moderate
and vigorous activity.
Patients were evaluated at five moments during the
study: baseline (physical examination, blood tests and
scales), at one-month and two-month follow up (weight
and BMI), at three-month follow up (physical examin-
ation, blood tests and scales), and at six-month follow
up (physical examination and blood tests). No inputs
about lifestyle were given after the 12-week program.
Sample size
The sample size was estimated based in an open pilot
study with 48 patients, where it was showed a weight
difference of -1 kg (weight loss) and a standard deviation
of 2 after three months. Taking into account a 35% of
drop-outs (α=0.05, power 0.8), the expected number in
each group was found to be 90 patients.
Statistical analysis
All randomized subjects were included in the initial ana-
lysis. Weight and BMI changes were defined as main
outcomes. Two-sided t-tests and chi-square tests were
used to analyze the differences between the groups at
baseline and during follow-up.
ANOVA with repeated measures was used to compare
the intervention versus standard care groups over time.
We describe two types of p value, one that represents
difference over time and the other that representsinteraction between groups. Analyses of the main
outcomes were based on the intention-to-treat analysis,
with the Last Observation Carried Forward (LOCF)
using weight and BMI measures of the last assessment
available. An alpha level of .05 was set for all statistical
tests. Data was analyzed using Statistical Package for So-
cial Sciences, version 15 (SPSS Inc, Chicago, Illinois).
Results
Randomization and participant characteristics
A total of 160 patients were included in the study, 81
were randomly allocated to the Lifestyle Wellness Pro-
gram (LWP) and 79 patients to the standard care (SC)
group. Figure 1 shows the CONSORT diagram of events
among participants of the study. Overall there were 34
dropouts for the three-month follow-up. Thirteen
patients assigned to the LWP group did not attend any
of the sessions as follows: a) four patients declined to
participate; b) one patient started new activities at the
same time of the group; c) four patients started working
in the beginning of the intervention; and d) four patients
were missed for unknown reasons. During the three-
month follow-up there were 8 dropouts in the LWP
intervention group (4 declined to participate, 3 had a re-
lapse, 1 missed for unknown reasons) and 13 in the
standard care (4 declined to participate, one started
other activities, 2 had a relapse, 3 started working, and 3
were missing for unknown reasons), leading to a re-
sponse rate of 78.7%. At six-month follow up we had 44
patients in the intervention group and 41 patients in the
standard care group, with a response rate of 53.1%.
As can be seen in Table 1, the social, demographic and
clinical characteristics did not differ significantly be-
tween the two groups at baseline.
Intervention adherence
Patients participating in the program were followed up
by the program coordinator who would call them in case
of absence in the session. The mean of attending
sessions was 9.1 (SD: 3.5), and 49 patients, i.e. 72.1% of
participants attended eight or more meetings.
Clinical and metabolic parameters at baseline
At baseline both samples were similar regarding clinical
and metabolic parameters such as weight, BMI, waist
measurement, blood pressure, blood glucose, total choles-
terol, HDL-cholesterol, LDL-cholesterol, triglycerides, in-
sulin, and HOMA-IR (p>0.05). The BMI (kg/m2) of the
two groups showed presence of being overweight, and the
SC group was slightly higher (29.9 kg/m2) than the inter-
vention group (29.1 kg/m2). 117 patients (73.1%) were tak-
ing second generation antipsychotics (25 risperidone, 40
olanzapine, 34 clozapine, 10 quetiapine, 5 ziprasidone, 3
aripiprazole, 18 (11.4%) were taking first-generation
Figure 1 CONSORT diagram: participation in the study.
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peridol, 4 other typical), and 24 patients (15.2%) were
taking an association of antipsychotics. We found no dif-
ference between both groups regarding the type of anti-
psychotic (p=0.254).
Changes over time
After three months, the intervention group (n= 60)
presented a decrease of −0.47 kg (CI 95% -1.23 to 0.3) and
the standard care group (n= 66) presented an increase of
0.46 kg (CI 95% -0.32 to 1.24), but this difference was not
statistically significant (group interaction p=0.093).
The BMI of the intervention group showed a decrease
of 0.14 kg/m2 (CI 95% -0.44 to 0.16) and the standard care
group presented an increase of 0.16 kg/m2 (CI 95% -0.11
to 0.43; p=0.135).After six months, the intervention group presented a de-
crease of 1.7 kg (CI 95% -3.17 to −0.23) and the standard
care group showed an increase of 0.01 kg (CI 95% -0.51 to
1.45; p=0.099).
Blood glucose decreased in both groups over time
after three months (p=0.029), however the decrease was
not statistically different between the two groups.
Both groups presented an increase in walking as mea-
sured by IPAQ walking (p=0.002), as well as an increase in
psychological domain of WHO-QoL quality of life scale
(p=0.014). However the increase was not statistically differ-
ent between the two groups on both scales.
Changes between groups
After three months there were no differences between
groups in waist, blood pressure, total cholesterol, HDL-
Table 1 The social, demographic and clinical characteristics of participants at baseline (n=160)
Variable Lifestyle wellness program (n= 81) Standard care (n= 79) p
Gender
Female/Male 31/50 33/46 0.747
Age 36.2 (9.9) 38.3 (10.7) 0.209
Marital status
Single/Married/Other (divorced, widow) 64/8/9 62/10/7 0.787
Ethnicity
Caucasian/Afro-American/other 60/11/10 58/15/6 0.444
Education, years
1-8/9-11/>11 years 17/ 47/17 20/43/16 0.808
Occupation
With/ without occupation 36/45 38/40 0.857
Diagnosis (SCID)
Schizophrenia/ other psychosis 72/7 69/8 0.792
Age of onset, years 23.2 (9.0) 22.8 (8.7) 0.805
Duration of illness, years 13.1 (10.3) 15.5 (9.9) 0.142
Antipsychotic drugs
First / Second generation/ Association /None 11/57/13/0 7/59/11/2 0.382
Duration of current antipsychotic treatment, years 5.1 (6.1) 4.0 (3.6) 0.209
PANSS positive 12.3 (5.1) 12.1 (4.5) 0.685
PANSS negative 16.7 (6.6) 18.7 (7.3) 0.133
PANSS general 27.4 (7.0) 30.7 (8.5 0.055
PANSS total 56.4 (15.1) 61.6 (17.5) 0.138
Calgary 2.6 (3.2) 2.8 (4.7) 0.233
GAF 60.4 (15.7) 58.9 (15.4) 0.596
CGI 3.2 (1.1) 3.4 (1.0) 0.571
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HOMA-IR (Table 2).
In addition there were no differences between groups
in ILSS, WHOQoL, Fagerström, DINE and IPAQ scores
(Table 3).
Intent-to treat analysis
The intent-to treat analysis was conducted only to
weight differences since it was our primary outcome.
The intent-to treat analysis included 146 patients, with a
dropout rate of 8.75%.
After three months patients in the intervention group
presented a decrease of 0.48 kg (CI 95% -0.65 to 1.13)
while the standard care group showed an increase of
0.48 kg (CI 95% 0.13 to 0.83; p=0.055).
After six months the intervention group presented
a decrease of 1.15 kg (CI 95% -2.11 to 0.19) and the
standard care group presented an increase of 0.5kg (CI
95% -0.42 to 1.42), and this difference was statistically
significant (p=0.017).Discussion
To our knowledge the present study is the largest ran-
domized clinical trial designed to evaluate the efficacy of a
lifestyle intervention (LWP) for weight gain management
in patients with schizophrenia and schizoaffective
disorders. At the end of the intervention (three months)
there was no significant difference between groups on
weight and BMI, or other metabolic parameters. However,
after six months, patients who received LWP had lost
1.15kg and the patients under SC had gained 0.5 kg, and
this difference was statistically significant, although the
magnitude of the difference was small and not clinically
significant. Therefore, the intervention group maintained
weight and presented a tendency to decrease weight after
6 months.
On a recent systematic review, Álvarez-Jiménez et al.
[16] reported ten different types of studies with non-
pharmacological interventions lasting from eight weeks
to six months to reduce weight gain in patients with
schizophrenia. Six of these studies included trials with
Table 2 Analysis of the clinical characteristics at baseline and after three month follow-up
Variables Lifestyle wellness program (n=60) Standard care (n=66) p
Baseline 3-month Baseline 3-month
Weight (kg) 81.1 (14.3) 80.7 (14.1) 84.3 (17.8) 84.7 (17.9) 0.093
BMI (kg/m2) 29.1 (4.7) 28.9 (4.7) 29.9 (5.2) 30.0 (5.2) 0.135
Waist (cm) 101.1 (11.2) 100.5 (11.0) 104.1 (13.6) 104.4 (14.1) 0.149
Systolic BP (mmHg) 115.7 (12.7) 114.1 (12.2) 118.3 (16.1) 115.6 (12.4) 0.655
Diastolic BP (mmHg) 78.1 (9.1) 75.9 (10.3) 78.6 (12.0) 78.8 (10.9) 0.304
Glucose (mg/dl) 96.6 (20.5) 94.3 (13.7) 101.2 (35.6) 96.9 (30.1) 0.497
Total Cholesterol (mg/dl) 197.7 (45.7) 191.7 (41.9) 197.1 (40.2) 194.2 (38.8) 0.513
HDL Cholesterol (mg/dl) 44.2 (13.0) 44.3 (12.6) 47.0 (13.7) 46.4 (11.9) 0.585
LDL Cholesterol (mg/dl) 120.2 (37.7) 115.4 (36.2) 115.7 (33.0) 113.3 (34.4) 0.562
Triglycerides mg/dl) 166.7 (95.6) 164.8 (85.1) 165.6 (102.7) 175.5 (112.9) 0.393
Insulin (μU/ml) 11.3 (10.5) 12.8 (12.5) 13.9 (12.1) 14.5 (10.3) 0.616
HOMA-IR 2.8 (3.1) 3.3 (5.1) 3.5 (3.3) 3.6 (3.2) 0.507
BMI: body mass index; BP: blood pressure; HOMA-IR: Homeostatic Model Assessment.
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and only one a combination of nutritional and exercise
interventions. Overall they found a significant weight re-
duction when intervention groups were compared to
treatment as usual and the magnitude of this reduction
was 2.56 kg (CI −3.2 to −1.92 kg, p< 0.001). There were
no differences between the types of intervention.
Some studies were designed to target patients who had
already gained weight. For instance, Kwon et al. [31],Table 3 Analysis of the secondary outcomes at baseline and a
Variable Lifestyle wellness progra
Baseline
ILSS 0.76 (0.1)
WHOQoL
Physical 60.2 (15.9)
Psychological 54.9 (18.0)
Social relations 53.9 (23.4)
Environmental 54.8 (15.6)
Rosenberg self esteem 12.1 (4.3)
Fagerström tolerance questionnaire 6.3 (2.1)
DINE
Fibers 40.1 (20.8)
Fat 32.0 (13.9)
Unsatured fat 9.8 (1.9)
IPAQ
Walking 843.4 (1113.5) 13
Moderate activity 1006.7 (2021.8) 91
Vigorous activity 750.6 (1677.8) 77
Total 2591.7 (3258.4) 31evaluated 48 patients comparing a 12-week individual life-
style intervention with standard care, and found weight
loss of 3.9 kg in the intervention group compared with
1.48 kg in the control group after three months (p<0.05).
Wu et al. [32] in a randomized controlled trial with 128
patients in first episode schizophrenia comparing placebo,
metformin, lifestyle intervention and metformin with life-
style for weight gain management, found that lifestyle
intervention and metformin alone and in combinationfter three month follow-up
m (n=60) Standard care (n=66) p
3-month Baseline 3-month
0.76 (0.1) 0.76 (0.1) 0.76 (0.09) 0.595
58.7 (15.4) 59.0 (16.6) 60.5 (17.4) 0.270
58.4 (18.9) 58.4 (16.8) 61.1 (19.3) 0.736
56.9 (22.2) 53.0 (25.5) 56.9 (24.5) 0.803
57.1 (14.4) 55.8 (14.2) 56.5 (16.2) 0.489
11.8 (4.8) 12.3 (5.0) 12.2 (5.0) 0.811
6.4 (2.7) 6.3 (2.7) 6.3 (2.7) 0.331
44.4 (17.9) 42.6 (18.2) 42.4 (17.1) 0.211
30.2 (12.3) 34.7 (14.9) 37.2 (14.7) 0.126
10.1 (1.6) 10.0 (1.7) 10.3 (1.2) 0.944
90.8 (2078.7) 670.6 (903.5) 1049.2 (1191.4) 0.410
0.2 (1618.4) 1007.8 (2002.2) 1446.7 (3701.7) 0.503
8.2 (1857.1) 559.5 (1626.2) 530.9 (1202.4) 0.873
16.6 (4234.1) 2314.4 (3167.9) 3088.5 (4787.2) 0.294
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gain. Lifestyle associated with metformin showed the best
effect on weight loss.
Another observational study of a lifestyle intervention
conducted with 373 patients from 49 Scandinavian cities
(314 on intervention and 59 controls) [33] found a mean
change of −0.5 kg (95% CI: -0.9;-0.2) in weight lost for the
intervention group and 0.9 kg (95% CI: 0; 1.8) increase for
the control group, after three months follow-up, very simi-
lar findings with this clinical trial.
In this study there were no statistically significant
differences between the groups for clinical and labora-
tory parameters associated with obesity. Blood glucose
decreased in both groups over time differently from
other studies that found an impact of intervention on
glucose and lipid profile [34,35].
Pharmacological interventions for weight loss in
schizophrenia have to take into account the risk of these
medicines exacerbating psychotic symptoms [10]. Life-
style interventions are safer and effective for promoting
decrease or maintenance of weight. In a recent system-
atic review of effectiveness of treatments for obesity in
adults Le Blanc et al. [36] found that behaviorally based
treatment resulted in 3-kg greater weight loss in inter-
vention than control participants after 12 to 18 months,
with more treatment sessions associated with greater
loss [36]. Controls generally lost little or did not gain
weight, whereas intervention groups lost 1.5 to 5 kg, an
average of 4% of the baseline weight [36]. It is note-
worthy that weight losses of as little as 5% in individuals
at risk of metabolic syndrome may result in clinically
meaningful reductions in morbidity and risk of early
mortality [37]. In addition, interventional studies that
have achieved approximately 5% reduction in body
weight together with increasing physical activity to at
least 150 min/week of moderate activity such as walking,
have resulted in a marked decreased in insulin resistance
and a major reduction (50-80%) in the risk for future
DM type 2 [11,13].
Limitations of this study include the short duration of
the interventions and follow up. Although longer
interventions are more appropriate for weight loss
programs, most of the studies reported so far were
conducted with a 12-week follow-up, similar to the
current study [31,38]. The number of participants in the
trial was slightly lower (160) than the estimated sample
size (180). As the SC showed a significant increase in
physical activity (walking), it is not possible to disregard
some contamination. This lifestyle intervention had pre-
viously been conducted at these sites selected for the
study, and this fact may have influenced the staff ’s
attitudes owed to increased awareness of physical health
monitoring. This problem does not affect the main
findings of the study, since it would contribute toincreasing the efficacy in the control group, decreasing
the odds of finding a significant difference with the
intervention group. It is noteworthy that motivation for
losing weight was part of the inclusion criteria for the
study added to the fact that these patients were under
care of programs directed by preeminent academic
departments in the country, where it is supposed to ex-
pect some sort of intervention for losing weight in the
control group. As health behaviors assessed in the study
were not different between the two groups it is unclear
the trajectory for weight change improvement in the ex-
perimental group.
As for the motivation factor it is worth noting that the
intervention has a minor impact on weight change in
the experimental group. Most of the studies did select
motivated individuals to lose weight because this is an
important factor of compliance. This intervention may
not work for those who have no intention to change
their lifestyle.
Weight management interventions for individuals with
severe mental disorders should be incorporated to clin-
ical practice since it is known the impact of obesity in
general health and its consequences as diabetes and car-
diovascular disorders. Lifestyle Wellness Program (LWP)
can be an interesting option due to the fact that it is
an easy and accessible intervention, which can be
incorporated on routine of community services and out-
patient facilities. Moreover, the cost of implementing
such intervention can be very low once it can be
delivered by non-specialist health workers of the existent
health team and in the same setting of the community
center.
Conclusion
This was a multicentric randomized clinical trial with a
lifestyle intervention for individuals with schizophrenia,
where the intervention group maintained weight. It is
reasonable to suppose that Lifestyle Interventions may
be important long-term strategies to avoid the tendency
of these individuals to increase weight. These group
interventions can be delivered at a low cost, are safer
than employing weight loss medicines, and may have
long-term impact on quality of life and increased
longevity.
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